Sapphire Pharmaceuticals (Europe) SRL
Sapphire Pharmaceuticals (Europe) reported total assets of 53,551 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Sep 2026).
The score of Sapphire Pharmaceuticals (Europe) shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -43 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Sapphire Pharmaceuticals (Europe)'s annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −104,413 € | ||||
| Equity | 26,802 € | ||||
| Cash | 20,885 € | ||||
| EBITDA | −68,303 € | ||||
| Total assets | 53,551 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Sep 2026
- Year ended 31 Dec 2024filed on 30 Sep 2025
- Year ended 31 Dec 2023filed on 30 Sep 2024
- Year ended 31 Dec 2022filed on 29 Sep 2023
- Year ended 31 Dec 2021filed on 30 Sep 2022
Sapphire Pharmaceuticals (Europe)'s financial analysis
- Solvency50.0%sector median: 45.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Sapphire Pharmaceuticals (Europe)
1 active director(s) in the register.
Sapphire Pharmaceuticals (Europe)'s shareholders and holdings →Sapphire Pharmaceuticals (Europe)'s publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0649.580.096
- VAT number
- BE0649580096
- Peppol
- Registered · 0208:0649580096 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 03 Mar 2016
- Registered office
- 8310 Bruges
- Latest accounts
- 2025 · filed on 29 Sep 2026
- Activity
- Wholesale of information and communication equipment (NACE 46500)
Sapphire Pharmaceuticals (Europe) (SRL) has been based in Bruges since 2016, active in: wholesale of information and communication equipment. For 2025, it reports a net loss of 104,413 € and equity of 26,802 €; its revenue is not published. Its solvency stands at 50.0%, above the median of its sector (45.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Sapphire Pharmaceuticals (Europe)
Companies in the same business, of comparable size and area, outside its group.
- Medica BNL Wholesale of pharmaceutical and medical goods Jabbeke · balance sheet 15,087 €
- GMC Wholesale of pharmaceutical and medical goods Anderlecht · balance sheet 43,513 €
- Innovative Coating Technologies Manufacture of other chemical products n.e.c. Deinze · balance sheet 782,496 €
- Bricon Manufacture of communication equipment Sint-Niklaas · balance sheet €3.14m
- Cepheid Benelux Manufacture of communication equipment Ghent · balance sheet €10.7m
- P&E Trading Retail sale of information and communication equipment Mont-Saint-Guibert · balance sheet 47,036 €
- Winback Benelux Wholesale of pharmaceutical and medical goods Mouscron · balance sheet 22,890 €
- PJ Labgoods Wholesale of pharmaceutical and medical goods Brasschaat · balance sheet 130,500 €
Frequently asked questions about Sapphire Pharmaceuticals (Europe)
What is the revenue of Sapphire Pharmaceuticals (Europe)?
Sapphire Pharmaceuticals (Europe) files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Sapphire Pharmaceuticals (Europe)?
In Belgium, the VAT number is the company number prefixed with BE: BE0649580096 for Sapphire Pharmaceuticals (Europe), if the company is VAT-registered. Its company number (CBE) is 0649.580.096.
Where is the registered office of Sapphire Pharmaceuticals (Europe)?
According to the CBE register, the registered office of Sapphire Pharmaceuticals (Europe) is in 8310 Bruges.
What is the equity of Sapphire Pharmaceuticals (Europe)?
At the close of the 2025 financial year, the equity of Sapphire Pharmaceuticals (Europe) amounts to 26,802 €, a solvency of 50.0% of total assets.
Who manages Sapphire Pharmaceuticals (Europe)?
The register lists 1 active mandates at Sapphire Pharmaceuticals (Europe). Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Sapphire Pharmaceuticals (Europe)
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →